The America Invents Act:

Changes in the Patent Laws of Special Interest to the Life Sciences Industry

November 4, 2011

After several years of unsuccessful attempts, Congress recently passed the Leahy-Smith America Invents Act (the ‘‘AIA’’),1 containing the most significant changes to the Patent Act in more than 60 years. President Obama signed the AIA into law on Sept. 16.2 This article presents an overview of the major provisions that are significant for practitioners in the life sciences.3

1 H.R. 1249 (112th Congress).
2 Pub. L. No. 112-29.
3 The authors recognize that there is no monolithic ‘‘life sciences industry’’ that speaks with one voice on all issues, but instead use this term to address views that may be common or shared among individuals and entities advancing or using technologies in the biomedical or biotechnological sciences.


The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.


Brian Wells

Matthew McFarlane

Related Publications

September 13, 2022
Patent Value: Scoring Patents Using Characteristics Of Patents In Litigation
Christopher K. Larus, Miles A. Finn, Congnan Zhan, Joseph (Yu) Chen, and Shelley Gilliss - les Nouvelles
August 25, 2022
May 13, 2022
Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
David Martinez, Zac Cohen - Los Angeles & San Francisco Daily Journal
April 19, 2022
Video Game Content Creators Face COPPA Liability Hazards
Matthew Woods, Austin Miller - Bloomberg Law
November 16, 2021
Fintiv Denials in Drug Cases
Steven C. Carlson
Back to Top